Title	Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
ID	4423560
External ID	133500685
Author
Published Date	Nov. 22, 2024, 7:35 a.m.
Summary	Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm Apt
Tags	None
URL	No URL
Sentiment	Negative: 0.00914 Neutral: 0.57915 Positive: 0.41171
Relevance	0.01802

Content ID	2641035
Key	4a826326-8860-49d8-b727-e2f5da9910d0
Content	Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm Aptevo Therapeutics Fri, Nov 22, 2024, 3:35 PM 9 min read In This Article: APVO +15.33% Key Questions What is Aptevo Therapeutics' focus and how is it positioned in the cancer treatment market? Aptevo Therapeutics is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The company is positioned as a leader in the development of bispecific antibodies, which are gaining prominence for their revolutionary therapeutic potential and expanding market opportunities. Aptevo's differentiated platforms and promising clinical results position it as a significant player in the expanding field of bispecific antibody-based therapies. (Source: Marvin White, President and CEO of Aptevo) Was this helpful? Yes No What is the potential of Aptevo's pipeline, and what are its lead candidates? Aptevo's pipeline has the potential to address some of the most challenging and aggressive forms of cancer in both blood and solid tumors. The company's lead candidates, mipletamig and ALG.APV-527, are being evaluated in clinical trials for the treatment of acute myeloid leukemia and solid tumors, respectively. Mipletamig has shown encouraging clinical performance, with a 90% reduction in leukemic blasts within 30 days of treatment initiation in a Phase 1b/2 trial. (Source: Aptevo Therapeutics press release) Was this helpful? Yes No What are the preclinical candidates in Aptevo's pipeline, and how do they work? Aptevo's preclinical candidates, APVO711, APVO603, and APVO442, represent diverse but complementary approaches to cancer treatment. These candidates were designed with safety, targeted efficacy, and combinability in mind. For example, APVO711 is a dual immune mechanism that acts as an immune checkpoint blockade plus immune activator, while APVO603 simultaneously engages two co-stimulatory molecules in the tumor. (Source: Aptevo Therapeutics press release) Was this helpful? Yes No What is the market potential for bispecific antibodies, and how does Aptevo plan to capitalize on this trend? The market for bispecific antibodies is expected to grow by as much as 44% through 2030. Aptevo plans to capitalize on this trend by continuing to develop its pipeline of bispecific antibodies, including its lead candidates mipletamig and ALG.APV-527. The company also plans to add another targeted asset to its pipeline in the near term. (Source: Grand View Research and Marvin White, President and CEO of Aptevo) Was this helpful? Yes No What are the risks and uncertainties associated with Aptevo's business and pipeline? Aptevo faces various risks and uncertainties, including the uncertainties inherent in the initiation, enrollment, and maintenance of patients in clinical trials, the availability and timing of data from ongoing clinical trials, and the impact of competitive products. Additionally, Aptevo is subject to macroeconomic conditions, such as rising inflation and interest rates, and geopolitical risks. (Source: Aptevo Therapeutics' filings with the Securities and Exchange Commission) Was this helpful? Yes No Generated by Yahoo Finance AI Yahoo Finance used generative AI to summarize key information from this article. Some details may be inaccurate. We take that seriously. Reporting mistakes helps us improve these summaries. Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment SEATTLE, WA / ACCESSWIRE / November 22, 2024 / Aptevo Therapeutics (NASDAQ:APVO), a leader in the development of novel bispecific antibodies for cancer treatment, provided additional details about its robust oncology pipeline which is poised to potentially address some of the most challenging and aggressive forms of cancer in both blood and solid tumors. As bispecific antibodies gain prominence for their revolutionary therapeutic potential and expanding market opportunities, Aptevo's differentiated platforms (ADAPTIR ® and ADAPTIR-FLEX ® ) and promising clinical results across two clinical programs (mipletamig and ALG.APV-527), together with preclinical assets (APVO711, APVO603 and APVO442) are demonstrating how bispecifics rationally differentiated for safety and targeted efficacy may impact the future of cancer care. The company plans to add another targeted asset to the pipeline in the near-term and looks forward to providing more detail about the new compound at that time. "Bispecifics are increasing in importance across the cancer therapeutic landscape and the market is expected to grow by as much as 44% through 2030. Fueled by their ability to engage multiple targets, bispecifics provide a technology that utilizes various mechanisms of action with an enhanced safety profile. Aptevo's focused yet diversified pipeline aligns with these industry trends, offering a compelling investment opportunity that may address critical therapeutic gaps," said Marvin White, President and CEO of Aptevo. (Grand View Research) The Potential of the Pipeline Aptevo's commitment to transforming cancer therapeutics is exemplified by its development pipeline, which features five bispecific antibodies, two clinical and three preclinical, targeting hematological malignancies and solid tumors. The company's focus on developing highly potent, safe, and versatile therapeutics positions it as a significant player in the expanding field of bispecific antibody based therapies. Lead Candidate Mipletamig for Acute Myeloid Leukemia (AML): Mipletamig, Aptevo's lead bispecific antibody, is currently in a frontline Phase 1b/2 combination trial, RAINIER, following positive results from earlier studies. The Company announced an initial efficacy response earlier this week where the first patient dosed experienced a 90% reduction in leukemic blasts within 30 days of treatment initiation, continuing the efficacy trend seen in prior mipletamig clinical studies. Story Continues Mipletamig is designed to engage the immune system and directly target AML cells, offering new hope for a patient population with historically poor outcomes. Mipletamig's encouraging clinical performance underscores the potential to transform AML treatment standards, reinforcing Aptevo's innovative approach to tackling blood cancers. Clinical Candidate: ALG.APV-527: ALG.APV-527 is being evaluated in a Phase 1 trial for solid tumors likely to express the tumor antigen 5T4. Tumor types treated to date include breast, colon, pancreatic and non-small cell lung cancer. Positive preliminary data from the study were presented at the European Society of Medical Oncology Congress in September and at the Society for Immunotherapy of Cancer conference earlier in November. These results showed that ALG.APV-527 demonstrated positive safety and tolerability across all cohorts, nine of 16 evaluable patients (56%) achieved stable disease (SD), and biomarker analysis confirmed immune activation in the tumor microenvironment. This drug has the potential to advance treatment in hard-to-treat solid tumors, demonstrating the versatility of Aptevo's technology across a wide range of cancer types. "As competitors face challenges in bispecific development, Aptevo continues to demonstrate resilience and success, particularly in safety-a crucial factor in the oncology space. With a focused strategic direction, proprietary technology, and a strong clinical foundation, Aptevo is well-positioned to lead the growing momentum in the bispecific antibody market," said Marvin White, President and CEO of Aptevo. "Our work is rooted in delivering groundbreaking therapies that harness the precision of bispecific antibodies to bring hope to patients facing some of the most devastating cancers. As we advance our pipeline, we remain steadfast in our commitment to innovation, collaboration, and, most importantly, improving patient outcomes." Preclinical Potential The Company's preclinical candidates represent diverse but complementary approaches to cancer treatment and were designed, like the clinical candidates, with safety, targeted efficacy and combinability in mind. APVO711 (PD-L1 x CD40 ): Dual immune mechanisms that act as an immune checkpoint blockade plus immune activator where CD40 only functions when both binding domains are engaged APVO603 (4-1BB x OX40 ): Broad solid tumor targeting that simultaneously engages two co-stimulatory molecules in the tumor and only functions when both binding domains are engaged APVO442 (PSMA x CD3) : Precision targeting of prostate cancer antigens with immune engagement driven by CD3 engagement on (cancer fighting) T cells which are intended to directly kill PSMA-expressing prostate tumor cells About Aptevo Therapeutics Aptevo Therapeutics Inc. (NASDAQ:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard of care venetoclax + azacitidine. Mipletamig has orphan status for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIR ® and ADAPTIR-FLEX ® . The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com . Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of its therapeutic candidates and potential use of any such candidates, including in combination with other drugs, as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR ® and ADAPTIR-FLEX ® platforms, statements related to Aptevo's technology utilizing various mechanisms of action and whether such mechanisms of action will improve patient outcomes, statements related to the progress of Aptevo's clinical programs, including initial results from the Phase 1b/2 dose optimization trial to further evaluate mipletamig in combination with venetoclax and azacitidine , whether further study of mipletamig in Phase 1b/2 trial focusing on a targeted patient population will continue to show clinical benefit, whether Aptevo's strategy will translate into an improved overall survival rate in acute myeloid leukemia, whether the mipletamig data in combination therapy and monotherapy will be indicative of later stage clinical trials, whether further study of ALG.APV-527 across multiple tumor types will continue to show clinical benefit, whether biomarker analyses will continue to confirm biological activity of ALG.APV-527, the possibility and timing of future preliminary or interim data readouts for mipletamig and ALG.APV-527, whether Aptevo's final trial results will vary from its preliminary or interim assessments, statements related to the progress of and enthusiasm for Aptevo's preclinical and clinical programs, statement related to Aptevo's expectation to add another targeted preclinical asset to the pipeline, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "believes," "expects," "potential," "designed," "engineered," "innovative," "initiate," "allow," "promise," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social, macroeconomic, and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation, enrollment and maintenance of patients in clinical trials, uncertainties inherent in the results of preliminary or interim data and preclinical and clinical studies being predictive of the results of later-stage clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of the Company's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the novel coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine as well as the war between Israel and Hamas, and macroeconomic conditions such as rising inflation and interests rates, increased market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances. Aptevo Therapeutics Miriam Weber Miller Email: IR@apvo.com or millerm@apvo.com Phone: 206-859-6629 SOURCE: Aptevo Therapeutics View the original press release on accesswire.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories
Content Reference URL	None

Data Source Name	Yahoo Finance News
Data Source Type	news
Data Source URL	https://finance.yahoo.com/
Description	Yahoo! Finance is a media property that is part of the Yahoo! network. It provides financial news, data and commentary including stock quotes, press releases, financial reports, and original content. It also offers some online tools for personal finance management.
Weight	10

DJDT

Versions

Package	Name	Version
Django		5.0.3
Python		3.11.8
coverage	Coverage	7.4.4
debug_toolbar	Debug Toolbar	4.3.0
django_extensions	Django Extensions	3.2.3
grappelli	Grappelli	3.0.8

Time

Resource usage

Resource	Value
User CPU time	26.887 msec
System CPU time	3.958 msec
Total CPU time	30.845 msec
Elapsed time	33.673 msec
Context switches	5 voluntary, 1 involuntary

Browser timing

Timing attribute	Timeline	Milliseconds since navigation start (+length)

Settings from app.settings

Setting	Value
ABSOLUTE_URL_OVERRIDES	`{}`
ADMINS	`[]`
ALLOWED_HOSTS	`['*']`
ALPACA_API	`'********************'`
APPEND_SLASH	`True`
AUTH0_CLIENT_ID	`None`
AUTH0_CLIENT_SECRET	`'********************'`
AUTH0_DOMAIN	`None`
AUTHENTICATION_BACKENDS	`['django.contrib.auth.backends.ModelBackend']`
AUTH_PASSWORD_VALIDATORS	`'********************'`
AUTH_USER_MODEL	`'auth.User'`
BASE_DIR	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe')`
CACHES	`{'default': {'BACKEND': 'django.core.cache.backends.filebased.FileBasedCache', 'LOCATION': '/var/tmp/django_cache'}}`
CACHE_MIDDLEWARE_ALIAS	`'default'`
CACHE_MIDDLEWARE_KEY_PREFIX	`'********************'`
CACHE_MIDDLEWARE_SECONDS	`600`
CELERY_BROKER_URL	`'redis://localhost:6379'`
CELERY_RESULT_BACKEND	`'redis://localhost:6379'`
CSRF_COOKIE_AGE	`31449600`
CSRF_COOKIE_DOMAIN	`None`
CSRF_COOKIE_HTTPONLY	`False`
CSRF_COOKIE_NAME	`'csrftoken'`
CSRF_COOKIE_PATH	`'/'`
CSRF_COOKIE_SAMESITE	`'Lax'`
CSRF_COOKIE_SECURE	`False`
CSRF_FAILURE_VIEW	`'django.views.csrf.csrf_failure'`
CSRF_HEADER_NAME	`'HTTP_X_CSRFTOKEN'`
CSRF_TRUSTED_ORIGINS	`[]`
CSRF_USE_SESSIONS	`False`
DATABASES	`{'default': {'ATOMIC_REQUESTS': False, 'AUTOCOMMIT': True, 'CONN_HEALTH_CHECKS': True, 'CONN_MAX_AGE': 600, 'ENGINE': 'django.db.backends.postgresql', 'HOST': '34.125.28.12', 'NAME': 'pennyloupe', 'OPTIONS': {'sslmode': 'require'}, 'PASSWORD': '********************', 'PORT': 5432, 'TEST': {'CHARSET': None, 'COLLATION': None, 'MIGRATE': True, 'MIRROR': None, 'NAME': None}, 'TIME_ZONE': None, 'USER': 'pennyloupe'}}`
DATABASE_ROUTERS	`[]`
DATA_UPLOAD_MAX_MEMORY_SIZE	`2621440`
DATA_UPLOAD_MAX_NUMBER_FIELDS	`1000`
DATA_UPLOAD_MAX_NUMBER_FILES	`100`
DATETIME_FORMAT	`'N j, Y, P'`
DATETIME_INPUT_FORMATS	`['%Y-%m-%d %H:%M:%S', '%Y-%m-%d %H:%M:%S.%f', '%Y-%m-%d %H:%M', '%m/%d/%Y %H:%M:%S', '%m/%d/%Y %H:%M:%S.%f', '%m/%d/%Y %H:%M', '%m/%d/%y %H:%M:%S', '%m/%d/%y %H:%M:%S.%f', '%m/%d/%y %H:%M']`
DATE_FORMAT	`'N j, Y'`
DATE_INPUT_FORMATS	`['%Y-%m-%d', '%m/%d/%Y', '%m/%d/%y', '%b %d %Y', '%b %d, %Y', '%d %b %Y', '%d %b, %Y', '%B %d %Y', '%B %d, %Y', '%d %B %Y', '%d %B, %Y']`
DEBUG	`True`
DEBUG_PROPAGATE_EXCEPTIONS	`False`
DEBUG_TOOLBAR_CONFIG	`{'SHOW_TOOLBAR_CALLBACK': <function <lambda> at 0x7ff664cdbec0>}`
DECIMAL_SEPARATOR	`'.'`
DEFAULT_AUTO_FIELD	`'django.db.models.BigAutoField'`
DEFAULT_CHARSET	`'utf-8'`
DEFAULT_EXCEPTION_REPORTER	`'django.views.debug.ExceptionReporter'`
DEFAULT_EXCEPTION_REPORTER_FILTER	`'django.views.debug.SafeExceptionReporterFilter'`
DEFAULT_FILE_STORAGE	`'django.core.files.storage.FileSystemStorage'`
DEFAULT_FROM_EMAIL	`'webmaster@localhost'`
DEFAULT_INDEX_TABLESPACE	`''`
DEFAULT_TABLESPACE	`''`
DISALLOWED_USER_AGENTS	`[]`
EMAIL_BACKEND	`'django.core.mail.backends.smtp.EmailBackend'`
EMAIL_HOST	`'localhost'`
EMAIL_HOST_PASSWORD	`'********************'`
EMAIL_HOST_USER	`''`
EMAIL_PORT	`25`
EMAIL_SSL_CERTFILE	`None`
EMAIL_SSL_KEYFILE	`'********************'`
EMAIL_SUBJECT_PREFIX	`'[Django] '`
EMAIL_TIMEOUT	`None`
EMAIL_USE_LOCALTIME	`False`
EMAIL_USE_SSL	`False`
EMAIL_USE_TLS	`False`
FIELD_ENCRYPTION_KEY	`'********************'`
FILE_UPLOAD_DIRECTORY_PERMISSIONS	`None`
FILE_UPLOAD_HANDLERS	`['django.core.files.uploadhandler.MemoryFileUploadHandler', 'django.core.files.uploadhandler.TemporaryFileUploadHandler']`
FILE_UPLOAD_MAX_MEMORY_SIZE	`2621440`
FILE_UPLOAD_PERMISSIONS	`420`
FILE_UPLOAD_TEMP_DIR	`None`
FIRST_DAY_OF_WEEK	`0`
FIXTURE_DIRS	`[]`
FORCE_SCRIPT_NAME	`None`
FORMAT_MODULE_PATH	`None`
FORMS_URLFIELD_ASSUME_HTTPS	`False`
FORM_RENDERER	`'django.forms.renderers.DjangoTemplates'`
GRAPPELLI_ADMIN_TITLE	`'Penny Loupe'`
GRAPPELLI_AUTOCOMPLETE_SEARCH_FIELDS	`{'auth': {'user': ('id__iexact', 'username__icontains')}}`
IGNORABLE_404_URLS	`[]`
INSTALLED_APPS	`['coverage', 'grappelli', 'django.contrib.admin', 'django.contrib.auth', 'django.contrib.contenttypes', 'django.contrib.humanize', 'django.contrib.messages', 'django.contrib.postgres', 'django.contrib.sessions', 'django.contrib.staticfiles', 'django_htmx', 'app.core.apps.CoreConfig', 'django_extensions', 'debug_toolbar']`
INTERNAL_IPS	`['127.0.0.1']`
LANGUAGES	`[('en', 'English')]`
LANGUAGES_BIDI	`['he', 'ar', 'ar-dz', 'ckb', 'fa', 'ug', 'ur']`
LANGUAGE_CODE	`'en-us'`
LANGUAGE_COOKIE_AGE	`None`
LANGUAGE_COOKIE_DOMAIN	`None`
LANGUAGE_COOKIE_HTTPONLY	`False`
LANGUAGE_COOKIE_NAME	`'django_language'`
LANGUAGE_COOKIE_PATH	`'/'`
LANGUAGE_COOKIE_SAMESITE	`None`
LANGUAGE_COOKIE_SECURE	`False`
LOCALE_PATHS	`[]`
LOGGING	`{}`
LOGGING_CONFIG	`'logging.config.dictConfig'`
LOGIN_REDIRECT_URL	`'/accounts/profile/'`
LOGIN_URL	`'/accounts/login/'`
LOGOUT_REDIRECT_URL	`None`
MANAGERS	`[]`
MEDIA_ROOT	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe/media')`
MEDIA_URL	`'/media/'`
MESSAGE_STORAGE	`'django.contrib.messages.storage.fallback.FallbackStorage'`
MIDDLEWARE	['django.middleware.security.SecurityMiddleware', 'whitenoise.middleware.WhiteNoiseMiddleware', 'django.contrib.sessions.middleware.SessionMiddleware', 'django.middleware.cache.UpdateCacheMiddleware', 'django.middleware.common.CommonMiddleware', 'django.middleware.csrf.CsrfViewMiddleware', 'django.contrib.auth.middleware.AuthenticationMiddleware', 'django.contrib.messages.middleware.MessageMiddleware', 'django.middleware.clickjacking.XFrameOptionsMiddleware', 'django_htmx.middleware.HtmxMiddleware', 'debug_toolbar.middleware.DebugToolbarMiddleware']
MIGRATION_MODULES	`{}`
MONTH_DAY_FORMAT	`'F j'`
NUMBER_GROUPING	`0`
OPENAI_API_KEY	`'********************'`
PASSWORD_HASHERS	`'********************'`
PASSWORD_RESET_TIMEOUT	`'********************'`
POLYGON_API_KEY	`'********************'`
PREPEND_WWW	`False`
QT_API_KEY	`'********************'`
QT_APP_ID	`'13d3cbab'`
QT_PASSWORD	`'********************'`
QT_USERNAME	`'kevin+dev3@pennyloupe.com'`
ROOT_URLCONF	`'app.urls'`
SCRAPER_API_KEY	`'********************'`
SECRET_KEY	`'********************'`
SECRET_KEY_FALLBACKS	`'********************'`
SECURE_CONTENT_TYPE_NOSNIFF	`True`
SECURE_CROSS_ORIGIN_OPENER_POLICY	`'same-origin'`
SECURE_HSTS_INCLUDE_SUBDOMAINS	`False`
SECURE_HSTS_PRELOAD	`False`
SECURE_HSTS_SECONDS	`0`
SECURE_PROXY_SSL_HEADER	`None`
SECURE_REDIRECT_EXEMPT	`[]`
SECURE_REFERRER_POLICY	`'same-origin'`
SECURE_SSL_HOST	`None`
SECURE_SSL_REDIRECT	`False`
SERVER_EMAIL	`'root@localhost'`
SESSION_CACHE_ALIAS	`'default'`
SESSION_COOKIE_AGE	`1209600`
SESSION_COOKIE_DOMAIN	`None`
SESSION_COOKIE_HTTPONLY	`True`
SESSION_COOKIE_NAME	`'sessionid'`
SESSION_COOKIE_PATH	`'/'`
SESSION_COOKIE_SAMESITE	`'Lax'`
SESSION_COOKIE_SECURE	`False`
SESSION_ENGINE	`'django.contrib.sessions.backends.db'`
SESSION_EXPIRE_AT_BROWSER_CLOSE	`False`
SESSION_FILE_PATH	`None`
SESSION_SAVE_EVERY_REQUEST	`False`
SESSION_SERIALIZER	`'django.contrib.sessions.serializers.JSONSerializer'`
SETTINGS_MODULE	`'app.settings'`
SHORT_DATETIME_FORMAT	`'m/d/Y P'`
SHORT_DATE_FORMAT	`'m/d/Y'`
SIGNING_BACKEND	`'django.core.signing.TimestampSigner'`
SILENCED_SYSTEM_CHECKS	`[]`
SQL_FILES_DIR	`'/mnt/disks/pennyloupe_disk/pennyloupe/app/core/sql'`
STATICFILES_DIRS	`[]`
STATICFILES_FINDERS	`['django.contrib.staticfiles.finders.FileSystemFinder', 'django.contrib.staticfiles.finders.AppDirectoriesFinder']`
STATICFILES_STORAGE	`'django.contrib.staticfiles.storage.StaticFilesStorage'`
STATIC_ROOT	`PosixPath('/mnt/disks/pennyloupe_disk/pennyloupe/static')`
STATIC_URL	`'/static/'`
STORAGES	`{'default': {'BACKEND': 'django.core.files.storage.FileSystemStorage'}, 'staticfiles': {'BACKEND': 'django.contrib.staticfiles.storage.StaticFilesStorage'}}`
TEMPLATES	`[{'APP_DIRS': True, 'BACKEND': 'django.template.backends.django.DjangoTemplates', 'DIRS': ['templates'], 'OPTIONS': {'context_processors': ['django.template.context_processors.debug', 'django.template.context_processors.request', 'django.contrib.auth.context_processors.auth', 'django.contrib.messages.context_processors.messages']}}]`
TEST_NON_SERIALIZED_APPS	`[]`
TEST_RUNNER	`'django.test.runner.DiscoverRunner'`
THOUSAND_SEPARATOR	`','`
TIME_FORMAT	`'P'`
TIME_INPUT_FORMATS	`['%H:%M:%S', '%H:%M:%S.%f', '%H:%M']`
TIME_ZONE	`'UTC'`
USE_I18N	`True`
USE_THOUSAND_SEPARATOR	`False`
USE_TZ	`True`
USE_X_FORWARDED_HOST	`False`
USE_X_FORWARDED_PORT	`False`
WSGI_APPLICATION	`'app.wsgi.application'`
X_FRAME_OPTIONS	`'DENY'`
YEAR_MONTH_FORMAT	`'F Y'`

Headers

Request headers

Key	Value
Accept	/
Accept-Encoding	gzip, br, zstd, deflate
Host	pennyloupe.com
User-Agent	Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)

Response headers

Key	Value
Content-Type	text/html; charset=utf-8

WSGI environ

Since the WSGI environ inherits the environment of the server, only a significant subset is shown below.

Key	Value
CONTENT_LENGTH
CONTENT_TYPE
PATH_INFO	/ticker/APVO/content/4423560
QUERY_STRING
REMOTE_ADDR	3.146.107.168
REQUEST_METHOD	GET
SCRIPT_NAME
SERVER_NAME	pennyloupe.com
SERVER_PORT	443
SERVER_PROTOCOL	HTTP/1.1

Request

View information

View function	Arguments	Keyword arguments	URL name
`app.core.views.app.ticker_content_detail`	`()`	`{'content_id': 4423560, 'ticker': 'APVO'}`	`ticker_content_detail`

No cookies

No session data

No GET data

No POST data

SQL queries from 1 connection

default 2.58 ms (3 queries )

	Query		Timeline	Time (ms)	Action
		SELECT "pl_content"."created_dt", "pl_content"."updated_dt", "pl_content"."status_id", "pl_content"."id", "pl_content"."key", "pl_content"."fetch_ref_id", "pl_content"."ticker", "pl_content"."publish_dt", "pl_content"."external_id", "pl_content"."published_by", "pl_content"."title", "pl_content"."summary", "pl_content"."tags", "pl_content"."url", "pl_content"."author", "pl_content"."author_reputation_score", "pl_content"."content_length", "pl_content"."sentiment_positive", "pl_content"."sentiment_negative", "pl_content"."sentiment_neutral", "pl_content"."sentiment", "pl_content"."relevance_score", "pl_content"."votes_positive", "pl_content"."votes_negative", "pl_content"."is_processing_flag", "pl_content"."data_source_id", "pl_content"."publisher_id" FROM "pl_content" WHERE "pl_content"."id" = 4423560 LIMIT 21SELECT ••• FROM "pl_content" WHERE "pl_content"."id" = 4423560 LIMIT 21		0.92
		Connection: default Transaction status: Idle /mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124) return self.get_response(request) /mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43) return self.get_response(request) /mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(1405) content = Content.objects.get(id=content_id)
		SELECT "pl_content_content"."created_dt", "pl_content_content"."updated_dt", "pl_content_content"."status_id", "pl_content_content"."id", "pl_content_content"."key", "pl_content_content"."content", "pl_content_content"."content_ref_url", "pl_content_content"."content_id" FROM "pl_content_content" WHERE "pl_content_content"."content_id" = 4423560 ORDER BY "pl_content_content"."id" ASC LIMIT 1SELECT ••• FROM "pl_content_content" WHERE "pl_content_content"."content_id" = 4423560 ORDER BY "pl_content_content"."id" ASC LIMIT 1		1.04
		Connection: default Transaction status: Idle /mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124) return self.get_response(request) /mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43) return self.get_response(request) /mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(1411) content_content = ContentContent.objects.filter(details=content).first()
		SELECT "pl_data_source"."created_dt", "pl_data_source"."updated_dt", "pl_data_source"."status_id", "pl_data_source"."id", "pl_data_source"."name", "pl_data_source"."type", "pl_data_source"."url", "pl_data_source"."description", "pl_data_source"."weight", "pl_data_source"."class_name", "pl_data_source"."class_params_json" FROM "pl_data_source" WHERE "pl_data_source"."id" = 2 LIMIT 21SELECT ••• FROM "pl_data_source" WHERE "pl_data_source"."id" = 2 LIMIT 21		0.62
		Connection: default Transaction status: Idle /mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/whitenoise/middleware.py in __call__(124) return self.get_response(request) /mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/django_htmx/middleware.py in __call__(43) return self.get_response(request) /mnt/disks/pennyloupe_disk/pennyloupe/app/core/views/app.py in ticker_content_detail(1415) data_source = content.data_source

Static files (717 found, 2 used)

Static file paths

None

Static file apps

grappelli
django.contrib.admin
django_htmx
app.core
django_extensions
debug_toolbar

Static files

css/pennyloupe.css: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/static/css/pennyloupe.css
img/penny_loupe_logo.png: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/static/img/penny_loupe_logo.png

django.contrib.staticfiles.finders.AppDirectoriesFinder (717 files)

Templates (6 rendered)

Template path

templates

Templates

ticker_content_detail.html: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/templates/ticker_content_detail.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7ff65340efc0>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/APVO/content/4423560'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff65340dda0>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7ff65340dda0>>'} {'content_detail': {'content': <Content: Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm - >, 'content_content': <ContentContent: Content ID: 2641035>, 'data_source': <DataSource: Yahoo Finance News>, 'publisher': None}, 'ticker': 'APVO'}
base.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/base.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7ff65340efc0>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/APVO/content/4423560'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff65340dda0>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7ff65340dda0>>'} {'content_detail': {'content': <Content: Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm - >, 'content_content': <ContentContent: Content ID: 2641035>, 'data_source': <DataSource: Yahoo Finance News>, 'publisher': None}, 'ticker': 'APVO'}
components/leftnav.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/leftnav.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7ff65340efc0>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/APVO/content/4423560'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff65340dda0>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7ff65340dda0>>'} {'content_detail': {'content': <Content: Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm - >, 'content_content': <ContentContent: Content ID: 2641035>, 'data_source': <DataSource: Yahoo Finance News>, 'publisher': None}, 'ticker': 'APVO'} {'block': <Block Node: leftnav. Contents: [<TextNode: '\n <div'>, <IncludeNode: template=<FilterExpression '"components/leftnav.html"'>>, <TextNode: '\n </di'>]>}
components/header.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/header.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7ff65340efc0>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/APVO/content/4423560'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff65340dda0>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7ff65340dda0>>'} {'content_detail': {'content': <Content: Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm - >, 'content_content': <ContentContent: Content ID: 2641035>, 'data_source': <DataSource: Yahoo Finance News>, 'publisher': None}, 'ticker': 'APVO'} {'block': <Block Node: header. Contents: [<TextNode: '\n\n '>, <IncludeNode: template=<FilterExpression '"components/header.html"'>>, <TextNode: '\n\n '>]>}
components/ticker_subnav.html: /mnt/disks/pennyloupe_disk/pennyloupe/app/core/templates/components/ticker_subnav.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7ff65340efc0>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/APVO/content/4423560'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff65340dda0>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7ff65340dda0>>'} {'content_detail': {'content': <Content: Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm - >, 'content_content': <ContentContent: Content ID: 2641035>, 'data_source': <DataSource: Yahoo Finance News>, 'publisher': None}, 'ticker': 'APVO'} {'block': <Block Node: content. Contents: [<TextNode: '\n\n <div class="uk-flex'>, <IncludeNode: template=<FilterExpression '"components/ticker_subnav.html"'>>, <TextNode: '\n <!-- /SUB NAV--'>, <Variable Node: content_detail.content.title>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.id>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.external_id>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.author>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.publish_dt>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.summary>, <TextNode: '</td>\n '>, <Variable Node: content_detail.content.tags>, <TextNode: '</td>\n '>, <IfNode>, <TextNode: '\n '>, <Variable Node: content_detail.content.sentiment_negative>, <TextNode: '   \n '>, <Variable Node: content_detail.content.sentiment_neutral>, <TextNode: '   \n '>, <Variable Node: content_detail.content.sentiment_positive>, <TextNode: '<br/>\n '>, <django.template.defaulttags.WidthRatioNode object at 0x7ff654269b10>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.sentiment_neutral>, <TextNode: '" style="width:'>, <django.template.defaulttags.WidthRatioNode object at 0x7ff654269f10>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.sentiment_positive>, <TextNode: '" style="width:'>, <django.template.defaulttags.WidthRatioNode object at 0x7ff65426a350>, <TextNode: '%;"></div>\n '>, <Variable Node: content_detail.content.relevance_score>, <TextNode: '</td>\n '>, <IfNode>, <TextNode: '\n '>, <IfNode>, <TextNode: '\n <li clas'>, <Variable Node: content_detail.data_source.name>, <TextNode: '</td>\n '>, <Variable Node: content_detail.data_source.type>, <TextNode: '</td>\n '>, <Variable Node: content_detail.data_source.url>, <TextNode: '" target="_blank">'>, <Variable Node: content_detail.data_source.url>, <TextNode: '</a></td>\n '>, <Variable Node: content_detail.data_source.description>, <TextNode: '</td>\n '>, <Variable Node: content_detail.data_source.weight>, <TextNode: '</td>\n '>]>} {'ticker': 'APVO'}
components/footer.html: /mnt/disks/pennyloupe_disk/pennyloupe/templates/components/footer.html; Toggle context
{'False': False, 'None': None, 'True': True} {'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'ERROR': 40, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30}, 'csrf_token': '<SimpleLazyObject: <function csrf.<locals>._get_val at ' '0x7ff65340efc0>>', 'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/APVO/content/4423560'>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff65340dda0>>), 'request': '<<request>>', 'user': '<SimpleLazyObject: <function ' 'AuthenticationMiddleware.process_request.<locals>.<lambda> at ' '0x7ff65340dda0>>'} {'content_detail': {'content': <Content: Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm - >, 'content_content': <ContentContent: Content ID: 2641035>, 'data_source': <DataSource: Yahoo Finance News>, 'publisher': None}, 'ticker': 'APVO'} {'block': <Block Node: footer. Contents: [<TextNode: '\n '>, <IncludeNode: template=<FilterExpression '"components/footer.html"'>>, <TextNode: '\n '>]>}

Context processors

django.template.context_processors.csrf: Toggle context
{'csrf_token': <SimpleLazyObject: <function csrf.<locals>._get_val at 0x7ff65340efc0>>}
django.template.context_processors.debug: Toggle context
{}
django.template.context_processors.request: Toggle context
{'request': <WSGIRequest: GET '/ticker/APVO/content/4423560'>}
django.contrib.auth.context_processors.auth: Toggle context
{'user': <SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff65340dda0>>, 'perms': PermWrapper(<SimpleLazyObject: <function AuthenticationMiddleware.process_request.<locals>.<lambda> at 0x7ff65340dda0>>)}
django.contrib.messages.context_processors.messages: Toggle context
{'messages': <FallbackStorage: request=<WSGIRequest: GET '/ticker/APVO/content/4423560'>>, 'DEFAULT_MESSAGE_LEVELS': {'DEBUG': 10, 'INFO': 20, 'SUCCESS': 25, 'WARNING': 30, 'ERROR': 40}}

Cache calls from 1 backend

Summary

Total calls	Total time	Cache hits	Cache misses
0	0 ms	0	0

Commands

add	get	set	get_or_set	touch	delete	clear	get_many	set_many	delete_many	has_key	incr	decr	incr_version	decr_version
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Signals

Signal	Receivers
class_prepared
connection_created	register_type_handlers
got_request_exception
m2m_changed
post_delete
post_init
post_migrate	create_permissions, create_contenttypes
post_save	create_initial_trade_position
pre_delete
pre_init
pre_migrate	inject_rename_contenttypes_operations
pre_save
request_finished	close_old_connections, close_caches, reset_urlconf
request_started	reset_queries, close_old_connections
setting_changed	reset_cache, clear_cache_handlers, update_installed_apps, update_connections_time_zone, clear_routers_cache, reset_template_engines, storages_changed, clear_serializers_cache, language_changed, localize_settings_changed, file_storage_changed, complex_setting_changed, root_urlconf_changed, static_storage_changed, static_finders_changed, auth_password_validators_changed, user_model_swapped, update_toolbar_config, reset_hashers, update_level_tags, uninstall_if_needed, clear_caches, StaticFilesStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties, FileSystemStorage._clear_cached_properties

Path	Location
.DS_Store	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/.DS_Store
grappelli/.DS_Store	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/.DS_Store
grappelli/js/grappelli.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/grappelli.js
grappelli/js/jquery.grp_related_m2m.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_m2m.js
grappelli/js/jquery.grp_autocomplete_fk.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_fk.js
grappelli/js/jquery.grp_autocomplete_generic.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_generic.js
grappelli/js/jquery.grp_timepicker.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_timepicker.js
grappelli/js/jquery.grp_collapsible_group.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_collapsible_group.js
grappelli/js/jquery.grp_related_generic.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_generic.js
grappelli/js/jquery.grp_related_fk.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_related_fk.js
grappelli/js/jquery.grp_collapsible.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_collapsible.js
grappelli/js/grappelli.min.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/grappelli.min.js
grappelli/js/jquery.grp_autocomplete_m2m.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_autocomplete_m2m.js
grappelli/js/jquery.grp_inline.js	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/js/jquery.grp_inline.js
grappelli/images/spritesheet-1694777276.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/spritesheet-1694777276.png
grappelli/images/backgrounds/loading-small.gif	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/loading-small.gif
grappelli/images/backgrounds/changelist-results.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/changelist-results.png
grappelli/images/backgrounds/ui-sortable-placeholder.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/ui-sortable-placeholder.png
grappelli/images/backgrounds/nav-grabber.gif	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/nav-grabber.gif
grappelli/images/backgrounds/messagelist.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/backgrounds/messagelist.png
grappelli/images/icons/ui-datepicker-next.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/ui-datepicker-next.png
grappelli/images/icons/link-external-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/link-external-small_hover.png
grappelli/images/icons/tools-arrow-up-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-arrow-up-handler_hover.png
grappelli/images/icons/date-hierarchy-back.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/date-hierarchy-back.png
grappelli/images/icons/tools-delete-handler-predelete.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-delete-handler-predelete.png
grappelli/images/icons/breadcrumbs-rtl.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/breadcrumbs-rtl.png
grappelli/images/icons/datepicker_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/datepicker_hover.png
grappelli/images/icons/tools-trash-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-trash-handler_hover.png
grappelli/images/icons/selector-add-m2m-vertical_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/selector-add-m2m-vertical_hover.png
grappelli/images/icons/tools-related-remove-handler-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-remove-handler-small_hover.png
grappelli/images/icons/sorted-descending.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/sorted-descending.png
grappelli/images/icons/breadcrumbs_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/breadcrumbs_hover.png
grappelli/images/icons/tools-viewsite-link_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-viewsite-link_hover.png
grappelli/images/icons/object-tools-add-link.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/object-tools-add-link.png
grappelli/images/icons/tools-related-edit-handler-small-disabled.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-edit-handler-small-disabled.png
grappelli/images/icons/tools-related-remove-handler-small-disabled.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-related-remove-handler-small-disabled.png
grappelli/images/icons/sorted-ascending.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/sorted-ascending.png
grappelli/images/icons/link-internal-rtl-small_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/link-internal-rtl-small_hover.png
grappelli/images/icons/pulldown-handler_selected.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/pulldown-handler_selected.png
grappelli/images/icons/tools-delete-handler_hover.png	/mnt/disks/pennyloupe_disk/pennyloupe/.venv/lib/python3.11/site-packages/grappelli/static/grappelli/images/icons/tools-delete-handler_hover.png

Content Detail

Versions

Time

Resource usage

Browser timing

Settings from app.settings

Headers

Request headers

Response headers

WSGI environ

Request

View information

No cookies

No session data

No GET data

No POST data

SQL queries from 1 connection

Static files (717 found, 2 used)

Static file paths

Static file apps

Static files

django.contrib.staticfiles.finders.AppDirectoriesFinder (717 files)

Templates (6 rendered)

Template path

Templates

Context processors

Cache calls from 1 backend

Summary

Commands

Signals